{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:43:39Z","timestamp":1793400219236,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1093\/mmy\/myy084","type":"journal-article","created":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T07:25:35Z","timestamp":1535873135000},"page":"534-541","source":"Crossref","is-referenced-by-count":6,"title":["The use of echinocandins in hospitalized children in the United States"],"prefix":"10.1093","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-8146","authenticated-orcid":false,"given":"Kevin J","family":"Downes","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia"},{"name":"Pediatrics, Perelman School of Medicine at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy","family":"Ellis","sequence":"additional","affiliation":[{"name":"Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia"},{"name":"Departments of Biostatistics, Epidemiology and Informatics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondra","family":"Lavigne","sequence":"additional","affiliation":[{"name":"Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia"},{"name":"Departments of Biostatistics, Epidemiology and Informatics"},{"name":"School of Veterinary Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bryan","sequence":"additional","affiliation":[{"name":"Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia"},{"name":"Departments of Biostatistics, Epidemiology and Informatics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theoklis E","family":"Zaoutis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia"},{"name":"Departments of Biostatistics, Epidemiology and Informatics"},{"name":"Pediatrics, Perelman School of Medicine at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T","family":"Fisher","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia"},{"name":"Departments of Biostatistics, Epidemiology and Informatics"},{"name":"Pediatrics, Perelman School of Medicine at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"2019061820000080200_bib1","first-page":"1232","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis","volume":"41","author":"Zaoutis","year":"2005","journal-title":"In: Clin Infect Dis"},{"key":"2019061820000080200_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"2019061820000080200_bib3","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1097\/INF.0000000000000431","article-title":"Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study","volume":"33","author":"Palazzi","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2019061820000080200_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.inf.0000078159.53132.40","article-title":"Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities","volume":"22","author":"Wisplinghoff","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2019061820000080200_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/INF.0b013e3181937fe0","article-title":"Caspofungin for the treatment of pediatric fungal infections","volume":"27","author":"Fisher","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2019061820000080200_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2334-12-151","article-title":"Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"12","author":"Doring","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2019061820000080200_bib7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/INF.0b013e3182737427","article-title":"Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates","volume":"31","author":"Steinbach","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2019061820000080200_bib8","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2019061820000080200_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019061820000080200_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019061820000080200_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/myc.12449","article-title":"Comparative effectiveness of fungicidal vs. fungistatic therapies for the treatment of paediatric candidaemia","volume":"59","author":"Vendetti","year":"2016","journal-title":"Mycoses"},{"key":"2019061820000080200_bib12","first-page":"Cd006343","article-title":"Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections","volume":"2","author":"Blyth","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2019061820000080200_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"2019061820000080200_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/tropej\/fmr025","article-title":"A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants","volume":"58","author":"Mohamed","year":"2012","journal-title":"J Trop Pediatr"},{"key":"2019061820000080200_bib15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/myc.12071","article-title":"Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC)","volume":"56","author":"Neoh","year":"2013","journal-title":"Mycoses"},{"key":"2019061820000080200_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cid\/cit679","article-title":"Decreasing rates of invasive candidiasis in pediatric hospitals across the United States","volume":"58","author":"Fisher","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019061820000080200_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jinf.2015.09.041","article-title":"Impact of antifungal prescription on relative distribution and susceptibility of Candida spp.: trends over 10 years","volume":"72","author":"Bailly","year":"2016","journal-title":"J Infect"},{"key":"2019061820000080200_bib18","doi-asserted-by":"crossref","first-page":"e0120452","DOI":"10.1371\/journal.pone.0120452","article-title":"Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008\u20132013: results from population-based surveillance","volume":"10","author":"Cleveland","year":"2015","journal-title":"PLoS One"},{"key":"2019061820000080200_bib19","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/JCM.00308-13","article-title":"Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2019061820000080200_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.diagmicrobio.2014.02.016","article-title":"Candidemia surveillance in Iowa: emergence of echinocandin resistance","volume":"79","author":"Matsumoto","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019061820000080200_bib21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.diagmicrobio.2010.06.015","article-title":"Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008\u20132009)","volume":"68","author":"Pfaller","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019061820000080200_bib22","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/jac\/dkt283","article-title":"Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study","volume":"68","author":"Gonzalez","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019061820000080200_bib23","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1128\/JCM.05474-11","article-title":"Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey","volume":"49","author":"Peman","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2019061820000080200_bib24","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1111\/j.1469-0691.2011.03720.x","article-title":"Candidaemia in a European Paediatric University Hospital: a 10-year observational study","volume":"18","author":"Tragiannidis","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2019061820000080200_bib25","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1111\/j.1469-0691.2011.03528.x","article-title":"Colonization by Candida in children with cancer, children with cystic fibrosis, and healthy controls","volume":"17","author":"Gammelsrud","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2019061820000080200_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jmii.2013.09.006","article-title":"Risk factors of mortality and comparative in vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia","volume":"47","author":"Lee","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"2019061820000080200_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/myc.12104","article-title":"Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species","volume":"57","author":"Cornely","year":"2014","journal-title":"Mycoses"},{"key":"2019061820000080200_bib28","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s12325-017-0534-7","article-title":"Comparison of efficacy and safety of caspofungin versus micafungin in pediatric allogeneic stem cell transplant recipients: a retrospective analysis","volume":"34","author":"Maximova","year":"2017","journal-title":"Adv Ther"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/57\/5\/534\/28683826\/myy084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T20:00:43Z","timestamp":1560888043000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/57\/5\/534\/5108495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,9,28]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myy084","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2018,9,28]]}}}